Triple therapy may turn inoperable liver cancer into operable tumors
NCT ID NCT07483359
First seen Mar 22, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests a combination of three treatments—chemotherapy infused into the liver (FOLFOX-HAIC), a targeted drug (lenvatinib), and an immunotherapy (tislelizumab)—in 38 adults with advanced liver cancer that has spread to the main portal vein. The goal is to shrink the tumor enough so that it can be surgically removed. Participants will receive the therapy and be monitored for up to a year to see if surgery becomes possible and how long they live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.